The rising popularity of GLP-1 therapeutics, including Ozempic, Wegovy, and Rybelsus, is largely attributed to their effectiveness in promoting weight loss, enhancing blood sugar control, and lowering the risk of cardiovascular diseases. Recently, researchers have identified a potential new benefit. A new clinical trial indicates that semaglutide, the active ingredient in these medications, may also slow down certain biological processes linked to aging.
Published in Nature Communications, this study provides the first randomized, placebo-controlled evidence that semaglutide may delay the accumulation of DNA markers associated with biological aging in adults living with HIV.
Semaglutide: A Potential Marker for Slowing Biological Aging
Researchers from the University of California, San Diego, and partner institutions analyzed data from a clinical trial involving 108 adults with HIV-related lipohypertrophy, a condition characterized by excess abdominal fat. About half of the participants received weekly semaglutide injections, while the others received a placebo for comparison.
To evaluate biological aging, scientists utilized several “epigenetic clocks,” which estimate biological age by assessing DNA methylation—the pattern of chemical tags that influence gene expression without altering the DNA sequence. These markers can indicate whether the body’s cells are aging at a faster or slower rate than expected.
According to lead author Dr. Michael Corey, an associate professor at the University of California, San Diego School of Medicine and the Stein Institute on Aging, individuals with HIV often experience accelerated biological aging, even with effective modern antiretroviral treatments.
Results from participants treated with semaglutide compared to those who received a placebo included:
- Delayed biological aging across multiple epigenetic clocks linked to inflammation and overall health of blood, brain, heart, kidney, liver, and metabolic functions.
- A 9% reduction in the pace of biological aging as measured by the DunedinPACE epigenetic clock.
- Significant slowing of biological processes associated with age-related diseases and mortality risk, as determined by the PCGrimAge epigenetic clock.
How Do GLP-1 Drugs Affect Aging?
Researchers suggest that semaglutide may influence aging through various interconnected pathways. GLP-1 drugs are known to reduce inflammation and enhance metabolic health, thereby potentially diminishing chronic immune activation—a key factor in accelerated aging among HIV-infected individuals. Furthermore, the drug may help in reducing visceral fat—fat that accumulates around internal organs—and ectopic fat in atypical locations. Lowering these harmful fat deposits may decrease inflammatory signals linked to aging throughout the body.
Emerging data also indicate that GLP-1 drugs might reprogram specific cells in different organs, an aspect that may clarify the broad effects observed across various aging clocks, according to Corey.
Potential Implications Beyond HIV
Although this study concentrated on those with HIV-related lipohypertrophy, researchers believe their findings could have wider implications.
Professor Corey stated, “Many biological processes related to HIV are also central to aging in the general population. These processes might manifest earlier or more prominently in individuals with HIV, allowing this community to pinpoint interventions that could enhance healthspan on a broader scale.”
Understanding Healthy Life Expectancy
Healthy life expectancy goes beyond mere longevity; it refers to the number of years spent in good health without significant age-related diseases.
Recent Research on Slowing Aging
The research team highlighted a pilot study published recently in npj Aging that examined 24 weeks of semaglutide treatment in patients with HIV and metabolic dysfunction-associated fatty liver disease (MASLD).
Key findings from the study included:
- 42% of participants demonstrated slower biological aging as per the DunedinPACE epigenetic clock, with greater liver fat reduction observed in this group.
- 34% showed slowed aging associated with mortality risk according to the PCGrimAge epigenetic clock.
- Nearly 49% had longer telomeres, the protective DNA caps at chromosome ends, indicating improved physical function post-treatment.
These combined studies contribute to the accumulating evidence that GLP-1 drugs can impact biological mechanisms involved in aging.
Proceed with Caution
Despite these promising results, researchers caution that semaglutide is not an anti-aging solution.
Corey emphasized, “We are not claiming that semaglutide reverses aging or rejuvenates individuals. The signal shows it may slow down certain biological aging processes. With the emergence of new GLP-1-based therapies, the field has a chance to explore whether different drugs in this category impact biological aging differently and to identify optimal patient profiles for treatment.”
Further clinical trials are essential for validating these results, understanding the duration of effects, and determining the most effective treatment protocols for both those with HIV and the wider population. Researchers also aim to assess whether combining GLP-1 medications with healthy lifestyle choices—such as diet, exercise, and quality sleep—could amplify the impact on biological aging.
Looking forward, the Stein Institute on Aging aspires to utilize these findings to develop a personalized “aging dashboard” based on epigenetic clocks. The objective is to allow clinicians to monitor biological aging precisely and create tailored interventions targeting the root causes of age-related diseases.
This research appeared in Nature Communications and was supported in part by the National Institutes of Health with grants P30 AI036214, R01DK121619, and UM1TR004528, in addition to the James B. Pendleton Charitable Trust. The associated research published in npj Aging was also funded by the National Institutes of Health (grants P30 AI036214, UM1 AI068634, UM1 AI068636, UM1 AI106701) and the James B. Pendleton Charitable Trust.
Corey serves as a scientific advisor for TruDiagnostic.
Source: www.sciencedaily.com